PeptideStack
5.2kquestions
20kanswers
220users

Would you re-test survodutide after four weeks at minus 20 °C, or accept the original certificate?

Asked 23 May 2026Modified 4 days agoViewed 5.3k times
6

The case in front of me: survodutide · four weeks · minus 20 °C.

The failure mode I am trying to avoid is making this decision emotionally.

I have twelve months in view and I would like the plan to survive that long.

How would you structure this, and what thresholds would you set in advance?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

832 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

749 questions
shareeditfollowflag
RS
askedrota_site55k3823 May 2026

5 Answers

Sorted by votes
38

Stated carefully, a certificate that reports one test result on one vial extrapolates to claim that all two hundred vials in the lot are identical, which is an assumption worth questioning.

The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.

The underlying point is that if the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
DB
answeredDr_Signe_Baldursdottir46k3811 Jun 2026
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
25

The honest statement is that unless you have tested multiple vials or have segregation data, you are making an assumption about lot homogeneity that may not hold.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
M4
answeredmz_411399k2584 Jul 2026
Any reason this would differ for a longer peptide? – low_dead_space 8 months ago
add a comment
18

In practice, the single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.

Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.

Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

Assume segregation is possible, and design your sampling to catch it if it exists.

edited 16 Jul 2026 by tri_gly_ala — updated for the 2026 guidance change

shareimprove this answerflag
TA
answeredtri_gly_ala48k383 Jul 2026
15

Thermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
KL
answeredkirsi_lahtinen45k3826 Jul 2026
12

Stated carefully, most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.

A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
BN
answeredbridget_nyathi16k176 Jul 2026

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.